COMMUNIQUÉS West-GlobeNewswire
-
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
18/06/2026 -
Grey Matters Announces Increase to Private Placement Financing to $1.25 Million and Closing of Offering
18/06/2026 -
Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
18/06/2026 -
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
18/06/2026 -
BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth
18/06/2026 -
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
18/06/2026 -
FDA Approves First Single-Dose Generic Treatment for Influenza
18/06/2026 -
R1 Accelerates Real-Time Adjudication with New Phare OS Intelligence Engine
18/06/2026 -
AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
18/06/2026 -
23andMe Research Institute Appoints Hillary Aiken as Head of Philanthropy & Development
18/06/2026 -
Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
18/06/2026 -
CDT Notes Strategic Investment into Sarborg and Expansion into Quantum Computing
18/06/2026 -
Lite Strategy Leads Strategic Investment in LitVM
18/06/2026 -
International Myeloma Foundation’s Black Swan Research Initiative Presents Data and Results of Phase 2 ASCENT Cure Trial at EHA 2026 Congress
18/06/2026 -
SRx Health Solutions Closes EMJX Acquisition and Launches AI-Driven Platform Strategy Under New Name and Brand, SRX Global, Focused on Investments in High-Conviction Operating Companies and Assets
18/06/2026 -
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
18/06/2026 -
Earth Science Tech, Inc. Reports Fiscal Year-End Financial Results for March 31, 2026
18/06/2026 -
COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO
18/06/2026 -
LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026
18/06/2026
Pages